The efficacy of N-acetylcysteine plus sodium bicarbonate in the prevention of contrast-induced nephropathy after cardiac catheterization and percutaneous coronary intervention: A meta-analysis of randomized controlled trials

International Journal of Cardiology

Volumn 221, Issue , 2016, Pages 251-259

  Zhao, Shi jie ^a   Zhong, Zhao shuang ^b   Qi, Guo xian ^a   Tian, Wen ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b SHENYANG MEDICAL COLLEGE   (China)

Author keywords

Cardiac catheterization; Contrast induced nephropathy; N acetylcysteine; Percutaneous coronary intervention; Sodium bicarbonate

Indexed keywords

ACETYLCYSTEINE; BICARBONATE; CONTRAST MEDIUM;

ARTICLE; CONTRAST INDUCED NEPHROPATHY; DIABETES MELLITUS; DRUG EFFICACY; GLOMERULUS FILTRATION RATE; HEART CATHETERIZATION; HUMAN; KIDNEY DYSFUNCTION; META ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); ACUTE KIDNEY INJURY; ADVERSE EFFECTS; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; PROCEDURES; TREATMENT OUTCOME; TRENDS;

ACETYLCYSTEINE; ACUTE KIDNEY INJURY; CARDIAC CATHETERIZATION; CONTRAST MEDIA; DRUG THERAPY, COMBINATION; HUMANS; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SODIUM BICARBONATE; TREATMENT OUTCOME;

EID: 84977629036     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.07.086     Document Type: Article

References (50)

1. [1] Thomsen, H.S., European Society of Urogenital Radiology guidelines on contrast media application. Curr. Opin. Urol. 17 (2007), 70–76.
2. [2] Barrett, B.J., Parfrey, P.S., Prevention of nephrotoxicity induced by radiocontrast agents. N. Engl. J. Med. 331 (1994), 1449–1450.
3. [3] Barrett, B.J., Contrast nephrotoxicity. J. Am. Soc. Nephrol. 5 (1994), 125–137.
4. [4] McCullough, P.A., Wolyn, R., Rocher, L.L., Levin, R.N., O'Neill, W.W., Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am. J. Med. 103 (1997), 368–375.
5. [5] Tepel, M., Aspelin, P., Lameire, N., Contrast-induced nephropathy: a clinical and evidence-based approach. Circulation 113 (2006), 1799–1806.
6. [6] Katzberg, R.W., Urography into the 21st century: new contrast media, renal handling, imaging characteristics, and nephrotoxicity. Radiology 204 (1997), 297–312.
7. [7] Nash, K., Hafeez, A., Hou, S., Hospital-acquired renal insufficiency. Am. J. Kidney Dis. 39 (2002), 930–936.
8. [8] Rihal, C.S., Textor, S.C., Grill, D.E., et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 105 (2002), 2259–2264.
9. [9] Solomon, R., Werner, C., Mann, D., D'Elia, J., Silva, P., Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N. Engl. J. Med. 331 (1994), 1416–1420.
10. [10] DiMari, J., Megyesi, J., Udvarhelyi, N., Price, P., Davis, R., Safirstein, R., N-acetyl cysteine ameliorates ischemic renal failure. Am. J. Phys. 272 (1997), F292–F298.
11. [11] Merten, G.J., Burgess, W.P., Gray, L.V., et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA 291 (2004), 2328–2334.
12. [12] Barrett, B.J., Parfrey, P.S., Clinical practice. Preventing nephropathy induced by contrast medium. N. Engl. J. Med. 354 (2006), 379–386.
13. [13] Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann. Intern. Med. 151 (2009), 264–269 (W64).
14. [14] Oremus, M., Wolfson, C., Perrault, A., Demers, L., Momoli, F., Moride, Y., Interrater reliability of the modified Jadad quality scale for systematic reviews of Alzheimer's disease drug trials. Dement. Geriatr. Cogn. Disord. 12 (2001), 232–236.
15. [15] Begg, C.B., Mazumdar, M., Operating characteristics of a rank correlation test for publication bias. Biometrics 50 (1994), 1088–1101.
16. [16] Chong, E., Poh, K.K., Lu, Q., et al. Comparison of combination therapy of high-dose oral N-acetylcysteine and intravenous sodium bicarbonate hydration with individual therapies in the reduction of Contrast-induced Nephropathy during Cardiac Catheterisation and Percutaneous Coronary Intervention (CONTRAST): a multi-centre, randomised, controlled trial. Int. J. Cardiol. 201 (2015), 237–242.
17. [17] Thayssen, P., Lassen, J.F., Jensen, S.E., et al. Prevention of contrast-induced nephropathy with N-acetylcysteine or sodium bicarbonate in patients with ST-segment-myocardial infarction: a prospective, randomized, open-labeled trial. Circ. Cardiovasc. Interv. 7 (2014), 216–224.
18. [18] Yang, K., Liu, W., Ren, W., Lv, S., Different interventions in preventing contrast-induced nephropathy after percutaneous coronary intervention. Int. Urol. Nephrol. 46 (2014), 1801–1807.
19. [19] Inda-Filho, A.J., Caixeta, A., Manggini, M., Schor, N., Do intravenous N-acetylcysteine and sodium bicarbonate prevent high osmolal contrast-induced acute kidney injury? A randomized controlled trial. PLoS One, 9, 2014.
20. [20] Mahmoodi, K., Sohrabi, B., Ilkhchooyi, F., Malaki, M., Khaniani, M.E., Hemmati, M., The efficacy of hydration with normal saline versus hydration with sodium bicarbonate in the prevention of contrast-induced nephropathy. Heart Views 15 (2014), 33–36.
21. [21] Heguilen, R.M., Liste, A.A., Payaslian, M., Gabriel Ortemberg, M., Martin Albarracin, L., Rita, B.A., N-acethyl-cysteine reduces the occurrence of contrast-induced acute kidney injury in patients with renal dysfunction: a single-center randomized controlled trial. Clin. Exp. Nephrol. 17 (2013), 396–404.
22. [22] Hafiz, A.M., Jan, M.F., Mori, N., et al. Prevention of contrast-induced acute kidney injury in patients with stable chronic renal disease undergoing elective percutaneous coronary and peripheral interventions: randomized comparison of two preventive strategies. Catheter. Cardiovasc. Interv. 79 (2012), 929–937.
23. [23] Lee, S.W., Kim, W.J., Kim, Y.H., et al. Preventive strategies of renal insufficiency in patients with diabetes undergoing intervention or arteriography (the PREVENT trial). Am. J. Cardiol. 107 (2011), 1447–1452.
24. [24] TY K, JH K, J L, JH S, KS K, BY C, Intravenous sodium bicarbonate and oral N-acetylcysteine for the prevention of contrast-induced nephropathy. Korean J. Med., 2011.
25. [25] Ratcliffe, J.A., Thiagarajah, P., Chen, J., et al. Prevention of contrast-induced nephropathy: a randomized controlled trial of sodium bicarbonate and N-acetylcysteine. Int. J. Angiol. 18 (2009), 193–197.
26. [26] Staniloae, C.S., Doucet, S., Sharma, S.K., et al. N-acetylcysteine added to volume expansion with sodium bicarbonate does not further prevent contrast-induced nephropathy: results from the cardiac angiography in renally impaired patients study. J. Interv. Cardiol. 22 (2009), 261–265.
27. [27] Maioli, M., Toso, A., Leoncini, M., et al. Sodium bicarbonate versus saline for the prevention of contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. J. Am. Coll. Cardiol. 52 (2008), 599–604.
28. [28] Heng, A.E., Cellarier, E., Aublet-Cuvelier, B., et al. Is treatment with N-acetylcysteine to prevent contrast-induced nephropathy when using bicarbonate hydration out of date?. Clin. Nephrol. 70 (2008), 475–484.
29. [29] Brar, S.S., Shen, A.Y.J., Jorgensen, M.B., et al. Sodium bicarbonate vs sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography: a randomized trial. JAMA - J. Am. Med. Assoc. 300 (2008), 1038–1046.
30. [30] Recio-Mayoral, A., Chaparro, M., Prado, B., et al. The reno-protective effect of hydration with sodium bicarbonate plus N-acetylcysteine in patients undergoing emergency percutaneous coronary intervention: the RENO study. J. Am. Coll. Cardiol. 49 (2007), 1283–1288.
31. [31] Briguori, C., Airoldi, F., D'Andrea, D., et al. Renal insufficiency following contrast media administration trial (REMEDIAL): a randomized comparison of 3 preventive strategies. Circulation 115 (2007), 1211–1217.
32. [32] Liu, Y.H., Liu, Y., Tan, N., et al. Predictive value of GRACE risk scores for contrast-induced acute kidney injury in patients with ST-segment elevation myocardial infarction before undergoing primary percutaneous coronary intervention. Int. Urol. Nephrol. 46 (2014), 417–426.
33. [33] Svensson, A.S., Kovesdy, C.P., Kvitting, J.P., Rosen, M., Cederholm, I., Szabo, Z., Comparison of serum cystatin C and creatinine changes after cardiopulmonary bypass in patients with normal preoperative kidney function. Int. Urol. Nephrol. 45 (2013), 1597–1603.
34. [34] Li, W.H., Li, D.Y., Han, F., Xu, T.D., Zhang, Y.B., Zhu, H., Impact of anemia on contrast-induced nephropathy (CIN) in patients undergoing percutaneous coronary interventions. Int. Urol. Nephrol. 45 (2013), 1065–1070.
35. [35] Persson, P.B., Hansell, P., Liss, P., Pathophysiology of contrast medium-induced nephropathy. Kidney Int. 68 (2005), 14–22.
36. [36] Yavari, V., Ostovan, M.A., Kojuri, J., et al. The preventive effect of pentoxifylline on contrast-induced nephropathy: a randomized clinical trial. Int. Urol. Nephrol. 46 (2014), 41–46.
37. [37] Li, W.H., Li, D.Y., Qian, W.H., et al. Prevention of contrast-induced nephropathy with prostaglandin E1 in high-risk patients undergoing percutaneous coronary intervention. Int. Urol. Nephrol. 46 (2014), 781–786.
38. [38] Van Praet, J.T., De Vriese, A.S., Prevention of contrast-induced nephropathy: a critical review. Curr. Opin. Nephrol. Hypertens. 16 (2007), 336–347.
39. [39] Sudarsky, D., Nikolsky, E., Contrast-induced nephropathy in interventional cardiology. Int. J. Nephrol. Renov. Dis. 4 (2011), 85–99.
40. [40] Morikawa, S., Sone, T., Tsuboi, H., et al. Renal protective effects and the prevention of contrast-induced nephropathy by atrial natriuretic peptide. J. Am. Coll. Cardiol. 53 (2009), 1040–1046.
41. [41] Caulfield, J.L., Singh, S.P., Wishnok, J.S., Deen, W.M., Tannenbaum, S.R., Bicarbonate inhibits N-nitrosation in oxygenated nitric oxide solutions. J. Biol. Chem. 271 (1996), 25859–25863.
42. [42] Fishbane, S., N-acetylcysteine in the prevention of contrast-induced nephropathy. Clin. J. Am. Soc. Nephrol. 3 (2008), 281–287.
43. [43] Lindinger, M.I., Franklin, T.W., Lands, L.C., Pedersen, P.K., Welsh, D.G., Heigenhauser, G.J., NaHCO(3) and KHCO(3) ingestion rapidly increases renal electrolyte excretion in humans. J. Appl. Physiol. 88 (2000), 540–550.
44. [44] Fliser, D., Laville, M., Covic, A., et al. A European Renal Best Practice (ERBP) position statement on the Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guidelines on acute kidney injury: part 1: definitions, conservative management and contrast-induced nephropathy. Nephrol. Dial. Transplant. 27 (2012), 4263–4272.
45. [45] Tepel, M., van der Giet, M., Schwarzfeld, C., Laufer, U., Liermann, D., Zidek, W., Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N. Engl. J. Med. 343 (2000), 180–184.
46. [46] Kang, X., Hu, D.Y., Li, C.B., Ai, Z.S., Peng, A., N-acetylcysteine for the prevention of contrast-induced nephropathy in patients with pre-existing renal insufficiency or diabetes: a systematic review and meta-analysis. Ren. Fail. 37 (2015), 297–303.
47. [47] Ali-Hassan-Sayegh, S., Mirhosseini, S.J., Rahimizadeh, E., et al. Current status of sodium bicarbonate in coronary angiography: an updated comprehensive meta-analysis and systematic review. Cardiol. Res. Pract., 2015.
48. [48] Zhang, B., Liang, L., Chen, W., Liang, C., Zhang, S., The efficacy of sodium bicarbonate in preventing contrast-induced nephropathy in patients with pre-existing renal insufficiency: a meta-analysis. BMJ Open, 5, 2015, e6989.
49. [49] McCullough, P.A., Adam, A., Becker, C.R., et al. Risk prediction of contrast-induced nephropathy. Am. J. Cardiol. 98 (2006), 27K–36K.
50. [50] Dangas, G., Iakovou, I., Nikolsky, E., et al. Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. Am. J. Cardiol. 95 (2005), 13–19.